Matwings Technology
Series A in 2024
Matwings Technology is a biotechnology company specializing in the design of functionally optimized proteins through advanced evolutionary methods. Utilizing proprietary techniques, the company focuses on computational chemistry and artificial intelligence-driven drug molecular design. Matwings collaborates with major pharmaceutical firms to facilitate early-stage research and development of innovative drugs targeting complex and clinically valuable challenges. By leveraging its expertise, Matwings aims to achieve significant breakthroughs in drug formulation, enhancing the potential for new therapeutic solutions.
Rapafusyn Pharmaceuticals
Series A in 2024
Rapafusyn Pharmaceuticals licenses technology related to a novel class of natural product-like macrocycles and develops novel pharmaceuticals aimed at treating diseases with unmet medical needs. It focuses on non-degrading molecular glues designed to target intracellular and transmembrane proteins that are difficult to drug using conventional methods, offering cell permeability, selectivity, tunability, and potential for oral delivery. The company supports drug discovery and development by enabling inhibition of challenging targets, contributing to the development of new therapeutic approaches.
Arnatar Therapeutics
Series A in 2024
Arnatar Therapeutics is a biopharmaceutical company focused on developing novel nucleic acid medications. It specializes in programmable RNA therapeutics for precision therapies targeting liver and extrahepatic metabolic and rare diseases, aiming to restore protein function and provide long-term disease control.
Tianhu Technology
Seed Round in 2024
Tianhu Technology provides drug research and development services through independent collaborative closed-loop iterations, deeply integrating AI solutions with the drug development and production process. Tianhu Technology is an innovative drug R&D company that offers high-throughput phenotypic screening and physical computing technology, as well as AI solutions that are deeply integrated into the drug R&D process.
Varnotech
Series B in 2024
Varnotech is a biotechnology company founded in 2019 that focuses on the development of vaccines, antibodies, and adjuvants aimed at combating various diseases and viruses. The company is dedicated to creating effective human vaccines and innovative adjuvants to enhance immune responses, thereby improving patient outcomes. Through its research and development efforts, Varnotech aims to address significant health challenges and contribute to global public health initiatives.
Myrobalan Therapeutics
Series A in 2024
Myrobalan Therapeutics is a biotechnology company dedicated to developing oral neurorestorative therapies that aim to reverse key pathologies associated with brain dysfunctions and central nervous system (CNS) conditions. By leveraging a profound understanding of neurological processes such as demyelination and neuroinflammation, the company utilizes innovative drug discovery tools to create selective and brain-penetrant therapeutic candidates. This focus on addressing the underlying mechanisms of CNS disorders positions Myrobalan Therapeutics to meet significant unmet medical needs, thereby providing healthcare professionals with effective therapeutic options for a large patient population suffering from these conditions. The company's dedicated team of scientists is committed to advancing research and development efforts in the field of CNS therapies.
Jushu Biotech
Seed Round in 2023
Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology.
Smartlens
Series A in 2023
Smartlens is a clinical-stage medical technology company focused on treating and diagnosing Glaucoma, a leading cause of irreversible blindness worldwide. Its flagship product, miLens, is an innovative eye pressure monitoring contact lens designed to improve early diagnosis, personalized treatment, and disease monitoring. This non-invasive, convenient solution aims to reduce the prevalence of glaucoma-related blindness, lower treatment costs, and alleviate the burden on lives and economies.
Novlead Biotech
Series B in 2023
Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.
Eaglenos is an IVD company that specialises in medical POCT, home health care devices, and health management systems. It focuses on chemistry, materials, electronics, software, machinery, and biomedical engineering. It helps in the advancement of electrochemistry, microfluidics, signal acquisition, and automation technologies.
Larkspur Biosciences
Series A in 2023
Larkspur Biosciences specializes in developing precision immunotherapies for specific patient groups with molecularly defined cancers. Its focus is on targeting the interaction between tumors and the immune system to stimulate robust, long-lasting responses.
Xunyuan Technology
Angel Round in 2023
Xunyuan Technology is a bio-refining and bio-manufacturing platform company based on non-grain carbon sources.
Eluminex Biosciences
Series B in 2023
Eluminex Biosciences is engaged in the research, development, and commercialization of innovative therapies aimed at addressing unmet medical needs in ocular health. The company focuses on ophthalmology and tissue regeneration, leveraging recombinant human collagen to develop therapeutic solutions. Its pipeline includes treatments designed to slow and mitigate the effects of aging and overuse on vision, ultimately enabling healthcare providers to offer improved care to their patients. Through its commitment to advancing the field of ophthalmology, Eluminex Biosciences seeks to enhance diagnostic and therapeutic options for ocular illnesses.
Jushu Biotech
Angel Round in 2023
Jushu Biotech is a medical engineering company that focuses on the research and development of synthetic biosensing technology.
Subtle Medical
Series B in 2022
Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.
Sipeng Technology
Seed Round in 2022
Sipeng Technology is a synthetic biology company that develops and supplies bio‑based products, focusing on negative‑carbon materials, polymer monomers, and high‑value compounds. The firm uses advanced synthetic biology techniques to create sustainable alternatives for industrial applications, enabling clients to produce bio‑based products with reduced environmental impact.
Regenacy Pharmaceuticals
Series B in 2022
Regenacy Pharmaceuticals is a Boston-based biopharmaceutical company founded in 2016 that develops therapies for peripheral neuropathies, hemoglobinopathies and certain oncology indications. Its approach centers on restoring normal protein function with oral, isoform-selective histone deacetylase inhibitors. The company is advancing drug programs that include ricolinostat to address sickle cell disease and beta-thalassemia, as well as additional HDAC inhibitor–based therapies for neuropathies and related conditions.
CytoNiche
Series B in 2022
CytoNiche specializes in 3D micro-structure engineering technology for stem cell research, translating Tsinghua University’s foundational research into commercial applications. The company develops 3D cell tissue engineering for high-quality stem cell cultures, injectable 3D micro-tissue therapies, and 3D drug screening microcarriers used in extensive drug screening operations. It provides reliable 3D micro-tissue products and services to research institutes, clinical institutions, stem cell companies, and drug discovery enterprises.
Zhengli Technology
Venture Round in 2021
Zhengli Technology specializes in the research, development, production, and sales of advanced invisible orthodontic products, dental restoration items, and professional dental software systems. The company aims to provide comprehensive, one-stop solutions for dental professionals both in China and globally. By focusing on innovative orthodontic appliances, Zhengli Technology enables patients to enhance their dental health and achieve straighter teeth, reflecting the company's commitment to improving dental care through technology and quality products.
Boaoxin
Venture Round in 2021
Biosion is a biotech company focused on the development of biologics to treat resistant, relapsed, residual immune, and oncologic diseases.
ITabMed is a clinical-stage biotechnology company based in Shanghai, China, founded in 2020 as a spin-off from Generon BioMed Ltd. The company specializes in the research and development of immunotherapy drugs aimed at treating cancer. It has developed an immunotherapy antibody technology platform that has produced two products, A-319 and A-337, which are currently undergoing phase I clinical studies. Additionally, ITabMed is advancing multiple candidate drug molecules that are in various stages of preclinical development, demonstrating its commitment to innovation in cancer treatment.
Novlead Biotech
Series B in 2021
Novlead Biotech is a company dedicated to enhancing human health through innovative medical technologies. It specializes in the development and manufacturing of medical devices that target cardiopulmonary, respiratory, and anti-infection applications. The company's primary focus is on the medical use of nitric oxide to address conditions such as pulmonary hypertension and infectious diseases. By leveraging its technological advancements, Novlead Biotech aims to improve treatment efficiency in hospitals and enhance the quality of life for patients.
NeuralGalaxy
Series A in 2021
Neural Galaxy is a brain science company that emerged from Harvard Medical School and the Massachusetts Institute of Technology. The organization focuses on addressing brain disorders through advanced software and hardware technologies. By leveraging breakthrough research in brain science, Neural Galaxy aims to enhance understanding of the brain and high-level intelligence. Its mission includes tackling significant challenges related to brain diseases and improving treatment options, ultimately contributing to a deeper comprehension of human cognition and enhancing overall societal intelligence.
Alebund Pharmaceuticals
Series B in 2021
Alebund Pharmaceuticals is a biopharmaceutical company specializing in the discovery and development of innovative therapies for renal diseases and associated chronic conditions. The company focuses on researching and commercializing treatments for a variety of kidney-related ailments, including chronic kidney disease, dialysis complications, nephropathy, diabetic kidney disease, and autosomal dominant polycystic kidney disease. With a diversified pipeline of drug candidates, Alebund Pharmaceuticals aims to deliver comprehensive, high-quality solutions to patients suffering from renal diseases, addressing both immediate and long-term healthcare needs in this critical area.
Cullgen Inc. is a clinical-stage biopharmaceutical company developing small molecule therapeutics based on its uSMITE platform, which enables targeted protein degradation by using novel E3 ligands to selectively degrade disease-causing proteins. The approach aims to address cancers, inflammatory and autoimmune diseases, and other conditions lacking effective therapies. Founded in 2018 and based in San Diego, Cullgen's pipeline includes degrader programs such as TRK and GSPT1, as well as other candidates like DAC.
Cardea Bio
Series A in 2021
Cardea Bio, Inc. is a biotechnology company based in San Diego, California, focused on developing and commercializing bioelectronics for research and diagnostics. Established in 2013, Cardea utilizes proprietary graphene-based digital biosensors to create advanced biosensor hardware, software, and molecular infrastructure, enabling precision healthcare through improved diagnostic capabilities. The company's product offerings include the AGILE R100, an innovative assay for drug discovery, and the AGILE R200, an automated high-throughput screening solution. Cardea's biosensors convert biomolecular interactions into digital data, allowing for real-time biological signal analysis and access to streaming multi-omics data. Their solutions cater to various applications in life sciences and healthcare, such as small molecule validation, antibody characterization, and biomolecular analysis.
Subtle Medical
Series A in 2020
Subtle Medical is a healthcare technology company that develops artificial‑intelligence software for magnetic resonance and positron emission tomography imaging. Its flagship products, SubtleMR and SubtlePET, are FDA‑cleared and CE‑marked tools that enhance image quality by reducing noise and sharpening detail, allowing scans to be performed faster and with lower radiation or contrast dose. The company’s deep‑learning algorithms integrate with any scanner without changing existing workflows, enabling imaging centers and hospitals to increase throughput and improve patient safety. Subtle Medical also offers a vendor‑agnostic AI platform that delivers analytics and support to clinical imaging providers. Founded in 2017 and headquartered in Menlo Park, California, the firm has received an NIH SBIR grant and an RSNA award for its GAD technology.
Biocytogen
Series D in 2020
Biocytogen specializes in developing gene-targeted animal models for life science research, offering customized mouse models, phenotype analysis, and extreme genome editing platforms. It also provides integrated solutions for antibody drug development, including animal model generation, therapeutic antibody discovery, and preclinical validation studies.
OncoImmune
Series B in 2020
OncoImmune is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for cancer and autoimmune diseases. Its pipeline includes CD24Fc, a fusion protein for preventing acute graft-versus-host disease, and ONC-392, a monoclonal antibody designed to reduce immune-related toxicities.
Regenacy Pharmaceuticals
Series A in 2020
Regenacy Pharmaceuticals is a Boston-based biopharmaceutical company founded in 2016 that develops therapies for peripheral neuropathies, hemoglobinopathies and certain oncology indications. Its approach centers on restoring normal protein function with oral, isoform-selective histone deacetylase inhibitors. The company is advancing drug programs that include ricolinostat to address sickle cell disease and beta-thalassemia, as well as additional HDAC inhibitor–based therapies for neuropathies and related conditions.
Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing antibody therapeutics for cancer treatment. Established in 2010, Apexigen specializes in immuno-oncology, creating therapies that aim to leverage the patient's immune system to effectively combat and eradicate cancer. The company's pipeline includes several promising candidates, such as APX005M and APX201 for immuno-oncology, along with additional programs targeting various oncology and inflammation conditions. Notably, its lead candidate, sotigalimab, is currently in clinical development, complemented by a range of preclinical immuno-oncology programs. Apexigen also utilizes its proprietary APXiMAB platform to discover novel antibodies targeting immune system pathways, underscoring its commitment to advancing innovative treatments in cancer care.
Lipidio Pharmaceuticals
Series A in 2020
Founded in 2018, Lipidio Pharmaceuticals is a biopharmaceutical company based in San Diego, California. It focuses on developing and manufacturing drugs to treat diseases associated with excess body fat, such as Prader Willi syndrome, nonalcoholic steatohepatitis (NASH), and obesity-related conditions.
Ansun Biopharma
Series B in 2019
Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.
Biocytogen
Series D in 2019
Biocytogen specializes in developing gene-targeted animal models for life science research, offering customized mouse models, phenotype analysis, and extreme genome editing platforms. It also provides integrated solutions for antibody drug development, including animal model generation, therapeutic antibody discovery, and preclinical validation studies.
Doctor Shaoyang
Series A in 2019
Doctor Shaoyang operates a medical platform focused on delivering psychological and mental health support services. The company offers a range of services, including health consultations, doctor-patient communication, one-on-one appointment consultations, and pre-diagnosis. This platform facilitates seamless online communication between patients and doctors while ensuring the protection of sensitive information. By prioritizing accessibility and privacy, Doctor Shaoyang aims to enhance the overall experience for users seeking mental health support.
Medtrum Technologies Inc., established in 2008, specializes in developing and delivering medical devices for diabetes management. Its product portfolio includes the A6 TouchCare System, a tubing-free, semi-closed loop insulin management system that integrates an insulin patch pump and continuous glucose monitoring (CGM) with predictive low glucose suspend features. The S6 EasySense is a waterproof, disposable CGM system providing real-time glucose readings for a week. The P6 EasyPatch is a disposable insulin pump offering adjustable basal rates and bolus on demand. Medtrum's cloud-based healthcare system, comprising the EasyTouch mobile app and EasyView web portal, consolidates patient data for self-management, family support, and healthcare provider access. With headquarters in Shanghai, China, Medtrum also operates in Düsseldorf, Germany; Hong Kong; and Watford, UK.
Cytek Biosciences
Series C in 2018
Cytek Biosciences, Inc. is a manufacturer and supplier of flow cytometry tools and equipment specifically designed for cancer and cell biology research. The company offers advanced flow cytometers, including the Cytek Aurora and Cytek Northern Lights, as well as the DxP Athena system, which utilizes proprietary technology to enhance the detection of dim populations in a multicolor format. In addition, Cytek provides the QbSure quality control program to ensure the optimal performance of its cytometers and a range of cFluor reagents tailored for use in multicolor applications. Established in 1990 and headquartered in Fremont, California, Cytek has expanded its presence internationally with locations in Bethesda, Maryland; Amsterdam, the Netherlands; Tokyo, Japan; and Shanghai, China. The company was previously known as Cytoville, Inc. before rebranding in August 2015.
Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the design and development of tissue-integrated sensors and biosensors aimed at improving diabetes management. Founded in 2009, the company focuses on creating biointegrated sensors that allow individuals to monitor their biochemical data in real-time, facilitating better management of personal health and chronic diseases. Profusa's technology aims to seamlessly integrate with the body, providing continuous, clinical-grade data that enhances health outcomes. In addition to its sensor technology, the company has developed software that offers biofeedback to support chronic disease management and promote healthy living.
Apexigen Inc. is a clinical-stage biopharmaceutical company based in San Carlos, California, focused on developing antibody therapeutics for cancer treatment. Established in 2010, Apexigen specializes in immuno-oncology, creating therapies that aim to leverage the patient's immune system to effectively combat and eradicate cancer. The company's pipeline includes several promising candidates, such as APX005M and APX201 for immuno-oncology, along with additional programs targeting various oncology and inflammation conditions. Notably, its lead candidate, sotigalimab, is currently in clinical development, complemented by a range of preclinical immuno-oncology programs. Apexigen also utilizes its proprietary APXiMAB platform to discover novel antibodies targeting immune system pathways, underscoring its commitment to advancing innovative treatments in cancer care.
Ansun Biopharma
Series A in 2018
Ansun Biopharma is a clinical-stage biopharmaceutical company based in San Diego that develops host-directed anti-viral therapies to prevent and treat life-threatening respiratory infections. The company focuses on therapies targeting the host rather than the virus, aiming to overcome viral mutation and immune evasion. Its pipeline includes Fludase, candidate for prophylaxis and treatment of influenza and parainfluenza infections, and Viradin, an intravenous therapy for sepsis, septic shock, and certain viral hemorrhagic fevers. It also advances TOSAP formulation technology to create microspheres and nanospheres for drug delivery. Through these programs, Ansun Biopharma seeks to provide therapies for severe viral diseases where traditional antivirals face limitations.
Refuge Biotechnologies
Series B in 2018
Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.
Biocytogen
Series C in 2018
Biocytogen specializes in developing gene-targeted animal models for life science research, offering customized mouse models, phenotype analysis, and extreme genome editing platforms. It also provides integrated solutions for antibody drug development, including animal model generation, therapeutic antibody discovery, and preclinical validation studies.
Eucure Biopharma
Series B in 2018
Eucure Biopharma, established in 2016 and headquartered in Beijing, China, is a biotechnology company focused on the discovery and development of innovative immuno-oncology targeted antibodies. Its pipeline comprises eight drug candidates, primarily targeting immune checkpoints, with several in the clinical trial application stage. The company offers services such as antibody production, in vivo and in vitro drug efficacy testing, and aims to improve the survival rate of tumor patients by developing effective antibody treatments.
Ligatech Bioscience
Series A in 2017
Ligatech Bioscience, established in 2014 and headquartered in Qingpu, China, specializes in the design, development, production, and sales of medical devices for orthopedic and sports medicine. Its product portfolio includes molecular weight polyethylene suture and striped titanium plates, along with artificial ligaments and fixation systems. The company also offers technical advice and services to its users.
EpimAb Biotherapeutics
Series A in 2017
EpimAb Biotherapeutics is a privately held biopharmaceutical company based in Shanghai that develops novel bispecific antibody therapeutics, with a focus on immuno-oncology and other high-value indications. The company uses its proprietary FIT-Ig (Fabs-In-Tandem Immunoglobulin) platform to generate bispecific molecules that combine antibody-like properties with improved design features, aiming to enhance target binding, pharmacokinetics and manufacturability. Through in-house research and development, EpimAb advances novel bispecific candidates intended to expand treatment options for patients and address remaining challenges in bispecific drug development.
OncoImmune
Series A in 2017
OncoImmune is a clinical-stage biopharmaceutical company focused on discovering and developing treatments for cancer and autoimmune diseases. Its pipeline includes CD24Fc, a fusion protein for preventing acute graft-versus-host disease, and ONC-392, a monoclonal antibody designed to reduce immune-related toxicities.
MicuRx Pharmaceuticals
Series C in 2016
MicuRx Pharmaceuticals is a biopharmaceutical company focused on discovering and developing novel antibiotics to combat drug-resistant bacterial infections. Founded in 2007 and based in Palo Alto, California, MicuRx operates with research and development facilities in both San Francisco, California, and Shanghai, China. The company's portfolio includes MRX-I, an oral antibiotic effective against multi-drug resistant gram-positive pathogens such as methicillin-resistant staphylococcus aureus and vancomycin-resistant enterococci; MRX-IV, a water-soluble prodrug form of MRX-I for intravenous use; MRX-V, an injectable antibiotic targeting gram-negative bacteria; and MRX-VIII, a polymyxin for gram-negative infections. Additionally, MicuRx's pipeline includes other antibacterial drugs designed to combat both gram-positive and gram-negative bacterial pathogens. The company employs a hybrid U.S./China business model, leveraging U.S. research and development with cost-efficient scientific resources in China. Shanghai MicuRx commercializes the agent contezolid in China, while global clinical studies are ongoing.
Refuge Biotechnologies
Series A in 2016
Refuge Biotechnologies, Inc. is a biotechnology company focused on developing innovative cancer immunotherapies. Founded in 2015 and based in Menlo Park, California, the company utilizes advanced gene-editing technology, specifically CRISPR-dCas, to create cell therapies that are capable of sensing their environment and conditionally regulating multiple genes at once. This approach enables Refuge to enhance the potency and specificity of its treatments, allowing for more effective targeting of cancer cells compared to traditional therapies that focus on a single target. Through its research and development efforts, Refuge aims to unlock the full potential of cell therapies in the fight against cancer.
Profusa, Inc. is a digital health technology company based in Emeryville, California, specializing in the design and development of tissue-integrated sensors and biosensors aimed at improving diabetes management. Founded in 2009, the company focuses on creating biointegrated sensors that allow individuals to monitor their biochemical data in real-time, facilitating better management of personal health and chronic diseases. Profusa's technology aims to seamlessly integrate with the body, providing continuous, clinical-grade data that enhances health outcomes. In addition to its sensor technology, the company has developed software that offers biofeedback to support chronic disease management and promote healthy living.